Ophthalmology

Teva’s Lucentis Biosimilar Gains UK Approval

May 17th 2022

By Skylar Jeremias

Article

The United Kingdom has approved Teva Pharmaceutical’s biosimilar (Ongavia) that references Lucentis (ranibizumab) for the treatment of several ophthalmic conditions.

Dr Sonia Oskouei Describes the Need for More Biosimilar Education for Ophthalmologists

May 8th 2022

By Skylar Jeremias

Video

Although the United States is looking to be one of the first countries to market an ophthalmology biosimilar, more education is needed to convince ophthalmologists of the safety and efficacy of biosimilars, said Cardinal Health's Sonia T. Oskouei, PharmD, BCMAS, DPLA.

Eye on Pharma: Alternatives to Blockbuster Ophthalmology, Diabetes Meds Progress

April 14th 2022

By Skylar Jeremias

Article

Access to new treatment options for ophthalmic conditions and diabetes is on the rise with the launch of Sandoz’ generic ocular hypertension medication, a new deal to bring a ranibizumab biosimilar to the Middle East, and the initiation of a trial for an insulin glargine biosimilar.

Real-world Study of Reference vs Biosimilar Ranibizumab for Treatment of Diabetic Macular Edema in India

April 7th 2022

By Deana Ferreri, PhD

Article

A real-world analysis found similar safety and efficacy profiles between a biosimilar ranibizumab (Razumab) and the reference product (Lucentis, Accentrix) in Indian patients with diabetic macular edema.

Health Canada Approves First Ranibizumab Biosimilar

March 10th 2022

By Skylar Jeremias

Article

Canada’s regulatory agency approved Samsung Bioepis’ Byooviz as the first ranibizumab biosimilar for the Canadian market for the treatment of ophthalmic conditions.

Biosimilar Business News Roundup: Russia Launches Omalizumab; Remsima Sales Soar; Xbrane Trial Results

February 16th 2022

By Skylar Jeremias

Article

Selexis and Generium launched an omalizumab biosimilar on the Russian market; Remsima sales hit a record high for Celltrion Healthcare; Xbrane Biopharma shares long-term results for its ranibizumab biosimilar.

Cardinal Health Report Sees 2022 as “Turning Point” for Biosimilars

February 8th 2022

By Mary Caffrey

Article

The year 2022 “is set to be a turning point” in the United States, as biosimilars are on their way to delivering $133 billion in aggregate savings by 2025, according to Cardinal Health's “2022 Biosimilars Report: The U.S. Journey and Path Ahead.”

Biogen to Sell Its Stake in the Biosimilar Venture Samsung Bioepis

January 28th 2022

By Laura Joszt

Article

In a deal to sell the 50% ownership stake, Biogen would receive up to $2.3 billion.

International Biosimilars Trade Group Appoints New Leadership for 2022

January 15th 2022

By Tony Hagen

Article

The International Generic and Biosimilar Medicines Association has appointed a veteran member, Vivian Frittelli, MBA, ACIS, to take over as chair.

Developers Advised to Challenge Regulatory Standards to Speed Development of Biosimilars

January 11th 2022

By Meir Rinde, MS

Article

In a recent paper, Sarfaraz K. Niazi, PhD summarizes some of his central ideas on the relevance of FDA biosimilar testing standards.